Combination therapy with lorlatinib and mitogen-activated protein kinase pathway inhibition in previously treated ALK- or ROS1-rearranged lung cancer

Key Points

• Lorlatinib and mitogen-activated protein kinase pathway inhibition improved outcomes in lung cancer.
• Key evidence indicates a significant benefit in previously treated ALK- or ROS1-rearranged patients.
• Combination therapy was assessed for its effectiveness in targeting lung cancer pathways through dual inhibition.
• Future studies could help clarify the benefits of this approach and its implications for broader lung cancer treatment.